Opexa Therapeutics, Inc. announced the establishment of a novel Multiple Sclerosis research partnership with the Myelin Repair Foundation, Inc. As part of this collaboration, Opexa and the MRF will work to identify therapeutically relevant biomarkers in MS that may provide important insight to support the continued development of Tovaxin(R), Opexa's T-cell vaccine currently in Phase IIb clinical testing in MS patients. In addition, biomarkers identified as part of the research program may also assist in guiding the discovery and development of novel diagnostics and treatments for MS.

Under terms of its collaboration with Opexa, the MRF will receive and analyze patient samples and clinical data from Opexa's Phase IIb clinical study with Tovaxin to identify biomarkers related to safety and efficacy of the therapy in MS patients. As part of this analysis, the MRF will leverage its network of leading MS researchers, as well as its proprietary biochemical and biological assays which are designed for the discovery and characterization of novel biomarkers that may have clinical use in diagnosing and/or treating MS..............

For the complete report please go to MSRC: MS Research News : Drugs : Tovaxin - http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1312